Home | Online Resources | UB Catalog | Campus Libraries | About UB Libraries | Forms | Search | Help
View PDF
Version
Return to Index
Making Connections With Commercial Partners
[image: background of bottles and chemistry equipment with a handshake in the foreground]
The Technology Development and Commercialization Branch
Making the Process Work
Technology transfer and commercialization as a process, is a relatively new way of doing business. The Federal Government and private industry have recently joined forces in cultivating products for the commercial marketplace. Until recently, a company may have found it difficult to access and commercially develop new technologies from federal laboratories. The NCI Technology Development and Commercialization Branch (TDCB) now makes it easier by providing companies access to more than 50 NCI laboratories and over a thousand Ph.D. or M.D. scientists, with additional laboratories at other Institutes,* in areas including:
The NCI Technology Development and Commercialization Branch, staffed by highly trained and experienced professionals, can facilitate the process of technology transfer by providing full-service support. On behalf of NCI and other Institutes,* TDCB is responsible for identifying and marketing new technologies, negotiating CRADAs, and managing the collaborative effort from ginning to end.
Each staff member works closely with the Institute's scientists in order to be fully informed and ready to assist companies in the successful development of new technologies for commercial application.
Success Stories
√ Taxol®. Taxol®, the most active anticancer agent discovered in over 20 years, has been approved by the Food and Drug Administration (FDA) for the treatment of refractory ovarian cancer and refractory breast cancer. The clinical development of Taxol® was the direct result of a CRADA between NCI and Bristol-Myers Squibb.
√ AIDS Test Kit. The AIDS test kit was patented and licensed as a result of NCI's very early technology transfer efforts. NCI's licensees currently market successful versions of this very important technology.
[image: chemist assembling an AIDs testing kit]
√ Azidothymidine (AZT), Dideoxyinosine (ddl), and Dideoxycytidine (ddC). NCI's role in the development, testing and successful clinical trials of the drugs azidothymidine (AZT), dideoxyinosine (ddI), and dideoxycytidine (ddC), confirmed their effectiveness as anti-retroviral agents against acquired immune deficiency syndrome (AIDS). NCI patents for ddI and ddC and their uses have been successfully licensed for commercialization.
√ The Journal of the National Cancer Institute (JNCI). The Journal of the National Cancer Institute is being privatized and developed into an electronic journal under a CRADA between NCI and Oxford University Press. The electronic journal will provide the public even greater access to leading edge scientific and medical information.
√ National "5 a Day for Better Health" Program Logo. NCI owns a trademark on the familiar "5 a Day-for Better Health" design, and uses it as an important part of its nationwide nutrition program in cooperation with state health departments and the fruit and vegetable industry, to increase fruit and vegetable intake for a healthier American public.
√ Development of a clinical pathology laser capture microdissection system for routine clinical use. NCI is currently collaborating with Arcturus Engineering to develop a clinical pathology laser capture microdissection system for routine clinical use. This system will allow the clinician to microdissect out cellular elements of interest during the diagnosis and treatment of cancer.
Collaborative Opportunities
√ Development of novel imaging technologies
√ Detection systems for identifying various infectious agents by type and subtype (e.g., HIV, HCV and HIV-1 type A, HIV-2 type B respectively)
√ Identification of monoclonal antibodies for diagnostic and therapeutic applications
√ Development of inhibitors of HIV transcription and viral replication
√ Identification and characterization of indicator proteins for applications in gene therapy, diagnostics and drug screening
√ Software development of statistical and machine learning methods for use in commercial applications such as drug design, medical care, fraud detection and medical administration
√ Phase I/II clinical trials of promising new anticancer and anti-AIDS compounds
Cooperative Research and Development Agreement (CRADA)
Making a Commitment to Develop Technology
A CRADA is an agreement between a Federal agency, or laboratory, and a nongovernment entity where both parties provide an intellectual contribution to the research project. Each party may contribute personnel, services, facilities, and equipment. In addition, the Government can also grant a collaborating party future intellectual property rights for any subject inventions that arise within the scope of the CRADA research plan. (See Federal Technology Transfer Act of 1986)
*Other NIH Institutes
For Further Information:
1. Technology Development and Commercialization Branch
National Cancer Institute
6120 Executive Blvd.
Suite 450
Rockville, MD 20852
Telephone: (301) 496-0477
Fax: (301) 402-2117
2. Technology Development and Commercialization Branch
National Cancer Institute
Frederick Cancer Research & Development Center
P.O. Box B
Frederick, MD 21702-1201
Telephone: (301) 846-5465
Fax: (301) 846-6820
E-mail: outreach@otd.nci.nih.gov Home page: http://www-otd.nci.nih.gov
The National Cancer Institute (NCI), the largest Institute of the National Institutes of Health, is actively seeking commercial partners to develop and commercialize federally developed technologies.
Whether your company is large or small, public or privately held, an important part of a successful business is to develop new, leading-edge products for the marketplace. An effective way to develop new products is through a collaboration with the Federal Government under a Cooperative Research and Development Agreement (CRADA). As shown by our success stories, federally developed technologies can enhance and add value to your product line.
[image: handshake in front of a tray of bottles]
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
National Institutes of Health
View PDF
Version
Return to Index